₦airaland Forum

Lexusgs430:
Know when to jump in and out..... 😁😂

I love that bro, that was why I said if one knows what he or she is doing and one map out strategies US stocks market is highly rewarding. Know what you are doing with God grace too you will stand before the kings and not mean men

Where are these comrades:

Sgtponzihater
Henrimoto

They have beaten my EYEN black and why but Mr. Eyen says it not over until it is over. Was gaining 23% earlier. 100-200% gain my target, paytienctly waiting.

BuchyD:
Calm down bro.... It's also one of the fastest way to be financially ruined. It could swing both ways.

To cap what you said here SAVA was doing I think around 35 or so and both PM and Regular hours sava moved from 35-3.8$ in just a single day because of their failed PH3 trial. That is why the market is not for the faint hearted and the lazy dudes. NSE is for such people but however, if one put efforts and map out strategies sure is VERY ACHIEVABLE and REWARDING. Part of my strategies is to have watch list and I monitor their price action any time it gets to my destination i jump in I have set prices and I don't buy above that just imagine those that bought at $30 and the nest day investment of 30k now 4k assumed it was 1k units bought. Imagine having to go through over 150 stocks is not for lazy dudes

Danger in biotech stocks SAVA from $35-4 in just one day due to failure in their trial mad ooo

EYEN +33% PM! very funny market, will set my sell limit according to how premarket will move. Very funny market trashed the other day 70% 2 days later chop another 20% may now run 100-200%

Celestialsword:
good observation,it's not too and never late,since you've discovered the gold mine, you can start mining

Yes oo bro, I told my bro to buy mtem he entered 0.40+ dipped 0.38 post market gold mining is 58% gain it will likely pump tomorrow have told him to set sell limit

BullBearMkt:
...as you know, you win some and loose some; what matter most is your risk management

Closed at 13% and currently doing 18% post market. my exit still remains 0.25-0.30 that is around 100-200% I will wait it

Celestialsword:
Stock to buy and hold forever
1. Amazon
Amazon (AMZN -1.87%) may be the ultimate growth company, as it's a leader in two high-growth markets: e-commerce and cloud computing. On top of this, Amazon is going all in on the latest promising area that some say will revolutionize the world, much like the telephone or the Internet. I'm talking about artificial intelligence (AI). Amazon is using AI to improve its own business through efficiency gains, and it's selling AI products and services to customers through its cloud computing unit, Amazon Web Services (AWS).

All of this has helped Amazon build a solid earnings track record, generally reporting billions of dollars in revenue and profit quarter after quarter. In e-commerce, Amazon's competitive moat is strong: It's built an extensive fulfillment network and an attractive subscription program that's kept customers loyal. And the company now continues to make deliveries faster and faster -- to save on costs and please the customer. That's a win-win situation.


NASDAQ: AMZN
Amazon
Today's Change
(-1.87%) -US$3.80
Current Price
US$199.08
As for cloud computing and AI, they go hand-in-hand. AI has helped AWS reach an annual revenue run rate of $110 billion. And this is key because AWS traditionally has been Amazon's profit driver.

Today, Amazon is trading for 40x forward earnings estimates. This isn't dirt cheap, but it's reasonable considering the company's strengths in such high growth areas and potential for the earnings momentum to continue well into the future.



2. Chewy
Chewy (CHWY 2.61%), like Amazon, is an e-commerce company, but this player specializes in one particular area -- serving your furry friends. Chewy sells everything from pet food and toys to prescription drugs and pet health insurance. And the company recently expanded into a brick-and-mortar business with the launch of veterinary clinics known as Chewy Vet Care. Finally, Chewy also brings in revenue through sponsored ads, a business that's in its early days but is exceeding the company's expectations.

What I like most about Chewy is a program that clearly shows its customers' loyalty -- and therefore offers us visibility on future revenue. This is Chewy's Autoship, a service that allows you to choose items you use regularly to be automatically reordered and shipped to you at a specific time. Autoship sales have steadily made up more than 75% of total sales quarter after quarter, and in the most recent quarter that percentage was more than 78%. Another number showing how much customers like Chewy is the net sales per active customer -- it climbed 6% to reach a record of $565 in the quarter.


NYSE: CHWY
Chewy
Today's Change
(2.61%) US$0.91
Current Price
US$35.52
Chewy also has a solid financial situation, with no debt and $695 million in cash, and a focus on managing operating expenses. And the company predicts its gross margin, today at about 29%, will fluctuate, but over time it will widen as higher-margin parts of the business grow.

All of this makes Chewy, today trading for 25x forward earnings estimates, an exciting growth player to buy and hold for the long term.

Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $378,269!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,369!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $476,653!*

© 1995 - 2024 The Motley Fool. All rights reserved.

Bro. All my year on nse to me was wasted if I had discovered US same yrs on nse I would have stopped 9-5 rat race but I thank God I will still get there as long as there is life and good health.

BullBearMkt:
...as you know, you win some and loose some; what matter most is your risk management

Sure bro, but stiil optimistics to exit at 0.20-0.25 but today trashing not a childs pla

BullBearMkt:
@aremso, curiosity made me check EYEN chart. Just wondering why you bought into the stock? Is it because of the massive fall?
EYEN outlook still bearish. YES! you can exit at 0.25 - smart plan; but risky!

Chopping serious flogs from shorties

yok:
TARGET TECHNICAL ANALYSIS EARLY MARKET COMMENTS 18 NOVEMBER 2024

Internationally the market is just giving indication that AI is the buzz word and it seems to have taken over every facet of our life (or where it is not been mentioned, something is there that people will now start calling AI in the future, e.g in biotechs, there are the robots that are used in performing operations, theses have always been there, check out 'intuitive surgical stock" but it is not yet being emphasised). So, uptrend will continue due to AI and fortunately too with the the Elon/Trump influence everything AI will likely boom and then drag the market along, we should know, also AI needs power (currently nuclear is the partner here plus anything that will reduce power cost ,SMCI is still a key factor here despite problem with Financial records).

So we need to allign ourself with the language of the market. Our trading ideas is alreadi in the hand of our causcus members. Today we are referencing a chartin plaform which any serious player in the market will know. For me I can ignore all websites, if I just have this platform plus 3 others, I am okay and I will come upwith top stop picks. So if you want to start knowing stocks to buy on your own without waiting for anybody, you will also know when to sell. The are the benefits our caucus members are enjoying!!! We do not have dull moments

Thanks for the heads up always, I will make other 10% of my holding in AI stocks. Let me begin to look for those growth badly damaged one among them that fits my strategies

BullBearMkt:
It seems you've mastered the art very well. Best of luck bro!

Bro u are still the Don oo just trying to study health stocks and see how I can make money out of them as they have catalyst apart from their financial statements unlike othe stocks that has Fundamentals majorly as their catalyst and sometimes they have same patterns. TCRT lost 65% in a day last year around august based on their failed PH3 trial EYEN lost 70% on Friday based on their failed PH3 trial too. So just trying to see how I can make few dollars from these stocks and above all na still God ooo as I don't know anything

BullBearMkt:
@aremso, curiosity made me check EYEN chart. Just wondering why you bought into the stock? Is it because of the massive fall?
EYEN outlook still bearish. YES! you can exit at 0.25 - smart plan; but risky!

Bro. TCRT had same pattern last year with over 200m float my average then was 0.09 then Mr. TCRT began to dig ground looking for what was not lost till it got to 0.04 . Boom from 0.04 the stock did 0.27 from 0.04 somebody here said she was tired of holding she sold like today the stock hit over 100% next day. You see all these health stocks has their uniqueness, even has this failed PH3 trial they can announce merger tomorrow now and u see it running 300%. A lot of madness in that health sector but I love the madness, that madness create money. ENSC did 157% wtout any info then madly Shorted the next day loosing around 90% was watching and at 0.34 I entered thinking that was the support and bounce back to 0.36 and I was on gain only to resume dump and voom I was loosing over 200$ until it gets to 0.30 where it established solid support. The rest is history am fluctuating between 94-103% gain and am holding till their PH3 trial and FDA next year by God grace. If both works fine the gap up Will be massive

Analyst can sometimes spoil person show ooo I entered EYEN after massive drop of 70% last week due to failure of their PH3 trial then after waiting endlessly to get it more at a crushed price then I manage bought at 0.113 then boom to 0.125 only for analyst do down grade from buy to hold wit TP from 12-2.😂😂😂😂

They are playing I will still exit at 0.25😂😂😂

Celestialsword:
The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings.

While recent market gains are largely driven by blue-chip giants, penny stocks quietly attract investors seeking untapped growth opportunities. Priced below $5 per share, the penny stocks offer a unique blend of risk and reward, with the potential to double or even triple initial investments.

The nature of these investments presents somewhat of a dilemma. How are investors supposed to separate the penny stocks that are ready to take off on an upward trajectory from those set to remain down in the dumps? This is where Wall Street’s analysts come into play.

We used the TipRanks database to uncover two compelling penny stocks that have earned Strong Buy ratings from the analyst community. According to the pros, these tickers are set to triple or more in the coming year. Let’s take a closer look.

Genelux Corporation (GNLX)

The first penny stock in the spotlight is Genelux, a clinical-stage biotech working in the world of immuno-oncology. Genelux’s research program is focused on the development of the next generation of cancer treatments, using oncolytic virotherapies to create therapeutic agents that can target a wide range of cancers. The company uses vaccinia virus to selectively replicate inside tumor cells and to kill them – while leaving the patient’s normal cells intact.

Genelux’s drug candidates target some of the more difficult-to-treat cancers, including a wide range of dangerous solid tumors, and are developed using the company’s CHOICE discovery platform. This is a proprietary platform that allows for the quick progression of new treatment candidates from early discovery through the clinical trial stages. Using its platform, Genelux has developed its leading oncolytic immunotherapy candidate, Olvi-Vec.

Olvi-Vec has been the subject of several early- and mid-phase clinical trials, but the current excitement around the drug candidate comes from the ongoing Phase 3 trial of the drug as an intraperitoneal (IPe) dosed treatment for platinum-resistant/refractory ovarian cancer (PRROC), a disease that is difficult to treat and has high unmet medical needs. The current Phase 3 trial will enroll up to 186 patients, and the company expects to release topline results in 2H25.

In addition to PRROC track, Genelux also has Olvi-Vec undergoing a Phase 2 trial in the treatment of non-small cell lung cancer (NSCLC). The interim readout for this trial is expected in the middle of next year.

Given these potential clinical milestones and GNLX’s current share price of $2.63, several members of the Street think that now is the right time to pull the trigger.

Roth MKM analyst Benjamin Paluch is particularly upbeat, suggesting that the Phase 3 ovarian cancer trial has the potential to be a game-changer for the stock.

“We view topline results from the Phase 3 study of Olvi-Vec in platinum resistant/refractory ovarian cancer as the key catalyst for the stock. Our base case is the trial is successful and shows a statistically significant progression-free survival (PFS)… Our base case assumes 70% upside with potential for a 100% gain under our bull case scenario and downside potentially limited to 30% under our bear case scenario… Recall, the FDA granted Fast Track designation to Olvi-Vec in platinum resistant/refractory ovarian cancer in November 2023, which suggests to us that the FDA could be flexible with its review, particularly in platinum refractory patients for which therapeutic options are limited,” Paluch opined.

To this end, Paluch rates GNLX a Buy along with a $10 price target. Should his thesis play out, a potential gain of 277% could be in the cards. (To watch Paluch’s track record, click here)

Other analysts don’t beg to differ. 4 Buy ratings and no Holds or Sells have been assigned in the last three months. Therefore, GNLX is a Strong Buy. The $15 average price target implies shares could climb 470% higher in the coming year. (See GNLX stock forecast)


SAB Biotherapeutics (SABS)

The next stock we’ll look at here is another biotherapeutic firm, SAB. This company has a focus on the treatment and prevention of immune and autoimmune diseases, a class of disease conditions that are known for the difficulties they present to both patients and care providers, in the form of dangerous symptoms and resistance to treatment.

SAB has developed an innovative genetic engineering platform, which it uses in the creation of new therapeutic agents. The company aims to develop multi-targeted, high-potency immunoglobulins (IgGs), and to do so without requiring human donors or even the use of convalescent plasma. While every biotech firm likes to say that it is unique, SAB is currently the only company on the scene capable of producing a truly polyclonal human antibody sans donor. These antibodies can be used to target diseases that present serious health challenges.

The company’s leading drug candidate, SAB-142, is a potential blockbuster if it pans out. SAB-142 offers a new approach to the treatment of type 1 diabetes (T1D), through disease modification. This drug candidate is a novel therapy for T1D, being a potentially redosable human antibody under study for its ability to delay the onset of clinical signs in, or the progression of, type 1 diabetes. SAB-142 is not insulin, nor would it require daily monitoring or management; in fact, the company sees a high chance that the drug could be administered on a one-yearly regimen.

In May of this year, SAB Biotherapeutics received clearance from the FDA to begin Phase 1 clinical testing of SAB-142 in the US. Enrollment for the Phase 1 trial has been completed, and the company expects to have a data readout by the end of this year. Early data showed no observation of serum sickness in the enrolled patients. SAB also has a Phase 1 trial underway in Australia, and expects to provide a data readout by year’s end.

These developments have drawn attention from Craig-Hallum analyst Albert Lowe, who has taken a closer look at the stock.

“We believe the company’s unique ability to produce human polyclonal antibodies (pAbs) offers profound opportunities for developing novel therapies, led by SAB-142. SAB-142 has a clear value proposition that builds on rabbit ATG’s (rATG) clinically validated mechanism of action in delaying the onset of T1D. As a human ATG, SAB-142 overcomes the safety limitations of rabbit ATG, making it a redosable disease-modifying therapy that enables long-term T1D disease prevention. We see opportunity for share appreciation as SAB-142 proceeds through development, where clinical data gives us confidence that SAB-142 can be the best-in-class therapy for long-term T1D prevention,” Lowe wrote.

In line with his optimistic take, Lowe rates SABS a Buy and set a price target of $11, which implies a potential upside of 237%. (To watch Lowe’s track record, click here)

Overall, all four of the recent analyst reviews on SABS are positive, making the Strong Buy consensus unanimous. The stock’s $3.26 trading price and $13.50 average target price combine to imply a 323% upside on the one-year horizon. (See SABS stock forecast)


To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

I think biotechs PH3 trials would be fantastic in the long run ENSC some hedgeies have been positioning since about 2 weeks ago with, 3 firm have taken up about 28% of the biotech company now. If their PH3 is successful the stock can do 1500% though nasdaq gave them 19th of December to hit 1$+ if the stock can get over 1$ and beat nasdaq wahala with success of PH3 trial+ FDA approval then it can do 10-25$ with time. Am still holding at 94% it was even 124% before the pull back I will hold till next year by God grace for the outcome of their clinical trials of PH3 then subsequent FDA approvals.

Health stocks will always carry 90% of my portfolio

BuchyD:
Calm down bro.... It's also one of the fastest way to be financially ruined. It could swing both ways.

Bro. Sure if u one doesn't know what he or she is doing, I select my battle to fight and I follow my strategies. Still remains the best for me. Have watched several YouTube videos of those who started with small money of 2-5k and they have grown the money to millions today still in the same market that looks tough some how so those guys don't have 2 heads. I play mostly in health sector cos that Is where I know there are catalyst that can give 100-300% in a day are. TSTP if I don't get the ticker wrong did 2,800% in 3 days. Oct last year. So I believe Fortune will be made here though not for Fainthearted and lazy but VERY ACHIEVABLE.

Sometimes I wonder why majority of guys don't discover the fastest way to multiply naira in Nigeria which is trading US stocks, am sure just a matter of time this space will create millionaire in dollars then billionaire in naira. No stock can do 100% on nse in a week

Tpst did 2800% last year October in 3days
Foxo had done 600% in a day last week
GNS did over 100% yesterday
Drug has done ove 700% few weeks ago
Ensc has done over 300% in one week

Penboy:
Purely Pump and dump

Ride the pump is purely pump and dump nothing no info to support the pump

Who remembered foxo which I put here around early this year, did almost 700% last week after been kept low for several months. Crazy market.!

OakPearl:
They are good swing candidates for the next few weeks.

Ok though have booked profits in some of them before still holding mlgo

Almost all the Chinese stocks on my rader have done minimum of 10% gain today

Holo
Mlgo
TANH
Lexh

OakPearl:
I have sold my CLSK bought yesterday at $8.97 at $9.58 today.
Not a bad scalp in under 24 hours!😁

I love this kind of trade

OakPearl:
Just 3 days ago, I made this post. NIO was $5.32 and Li $22.20.
Now, NIO has returned 21% selling for $6.48 and Li 17% up selling for $26.12.
No bond, fixed deposit account, mutual fund or treasury bill can fetch you such returns in just 3 days!
Stop playing!!!

God bless you my brother that is why is faster to make it big in US stocks because a stock can do 20% in just 20mins of trading. Just to do more works and research

OakPearl:
US STOCKS DAY TRADE PICKS!
The pre-market is heating up and I’ve got my eyes on some movers.

Here’s what I’m watching today!
✅BATL Long >4.75 Short < 4.45
✅XPON Long > 0.1372 Short < 0.1252
✅BNZI Long > 5.59 Short < 4.62
✅LFLY Long >2.75 Short < 2.40
✅TNON Long > 6.80 Short < 6.60
✅GDHG Long > 4.41 Short < 3.88

Decide when to take profits based on price and volume action.
Happy trading.

Some of these stocks are on my watch list but not on bamboo.

OakPearl:
The one I know is not exactly I. The US but accepts Nigerians as long as you can start with a minimum deposit of $2,500.

Hope they can allow trading premarket, post market and shorting. Momoo has all the stocks on my watch list but the problem is they don't accept Nigerians

OakPearl:
Happy Monday!
FOR TODAY’S DAY TRADING PICKS ONLY.
Here’s what I’m watching today in the US market:

✅BBLG Long > 1.31 Short < 1.12
✅DRMA Long > 2.57 Short < 2.27
✅NCNA Long > 7.13 Short < 6.23
✅XCUR Long> 2.70 Short< 2.43
✅VRAX Long> 4.10 Short< 3.52

Bro welcome back, appreciate your creation of this forum where millionaires are made. Kudos. Also thanful to yok for making this space lively, being a while i came here.

Good day guys, being a while. please is there any broker in US that accept nigerians

Onboard1:
Pls which stocks are on your watch list?

Bro the list is long ooo I just calculated around 170 now still never finished counting so I can't list here pls

Phraences:
Hello Sir. Just curious. Do you have a day job? Like 9-5? I am always wanting to invest in US stocks but it seems it requires constant monitoring especially those that can give 100% and above Like you have to monitor news, trends etc to know when to buy or sell.

If you have a 9-5 when do you have time to do all this?

I want to escape from the drudgery of 9-5 through the stock market but it is still the same 9-5 preventing me from starting.

U can keep your 9-5 and still make fortune in us stock market just draw u a strategies and follow it, I have over 120 stocks on my watch list and I monitor the movement to get their strong support and resistance level and also monitor their earnings. Before I sleep I checked them randomly to know my next stock to fall to. I trade penny stocks and at least reasonably I know their movements, when u are in a penny from a very strong support level even it is going down my losses is minimal and when it spikes 50-100% that is the time to exit. If u don't map out strategies to use while holding your 9-5 then u not ready to prepare for eventuality. 9-5 will always not give u time to prepare for your financial future is u that will create something for yourself, I don't believe anything is not possible no matter how hard as long as there is a record that someone has done it successfully unless if am not interested

With the outbreak of MPOX some health stocks will run koloba koloba. That sector remains the best for me, one catalyst or the other

Chijohn42k:
I mean't how much can I invest on stock for me to be in profit despite Bamboo buying and selling fee. Thanks in advance.

Lolll I can't say oooo it depends on your pocket ooo and also depends on the stock price u are buying a stock on my watch list did 300% yesterday before pulling back( INM) and many of the have done from 5-300% gain just yesterday. The following I think will help you

1. Your type of investor
2 the sector
3. Price range of stocks
4 . Your risk tolerance

Even if u have 100 dolls u can make fortune out of it. Have been so bullish on HOLO since last week and it eventually did like 70-100% between Monday and Tuesday so if u have 100 dolls u have doubled it then you move to another stock. But for me I will say start with minimum of 100-200dolls then know what u are doing cos US stock market is not for lazy dudes and not for faint hearted but VERY REWARDING. Most stocks on my watch list from where I pick has been under my rader for long , I researched them kept them under my watch and at the right time I strike.